<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The specific <z:chebi fb="0" ids="26995">thromboxane</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, S18886, was evaluated for prevention of coronary <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-reperfusion in anesthetized canines </plain></SENT>
<SENT sid="1" pm="."><plain>For the primary <z:mp ids='MP_0005048'>thrombosis</z:mp> study in left circumflex (LCX) coronary artery, 26 dogs were randomized to receive either vehicle (n = 7) or intravenous S18886 (0.3 mg/kg, n = 6; 1.0 mg/kg, n = 6; and 3.0 mg/kg, n = 7) </plain></SENT>
<SENT sid="2" pm="."><plain>The respective times to occlusion after S18886 were as follows: 56.8 +/- 9.3, 83.5 +/- 14.9, and 92.4 +/- 15.7 minutes compared to 43.3 +/- 8.2 minutes after vehicle </plain></SENT>
<SENT sid="3" pm="."><plain>S18886 caused a minimal increase in tongue <z:mp ids='MP_0001914'>bleeding</z:mp> time and a significant decrease in ex vivo platelet aggregation to <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> or U46619 </plain></SENT>
<SENT sid="4" pm="."><plain>Another 37 dogs were randomized to receive placebo (n = 12), <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> 1.0 mg/kg p.o </plain></SENT>
<SENT sid="5" pm="."><plain>QDX3 (n = 9), <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> + S18886 0.3 (n = 9) or 1.0 (n = 7) mg/kg intravenous </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> produced a 50% reduction in <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi>-induced platelet aggregation and a slight increase in the time to occlusion </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> + S18886 1.0 mg/kg prevented occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in most of the coronary vessels over 6 hours </plain></SENT>
<SENT sid="8" pm="."><plain>S18886 did not alter myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size in the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion model </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, S18886 alone caused a dose-dependent prolongation in the time to primary occlusive coronary artery <z:mp ids='MP_0005048'>thrombosis</z:mp>, whereas S18886 + <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> displayed effective in preventing occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation with only a moderate increase of tongue-<z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
</text></document>